Compare Bit Digital Inc (BTBT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

BTBT trades at $1.485, up 14.23% in the last 24 hours, but remains in a bearish technical trend. The company reported a net loss of $80.32 million on $113.56 million revenue for 2025, with a negative net income margin of -145.45%. Recent earnings have missed expectations, though analyst consensus is a Buy with a $5.12 average price target.

The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing activities. Key risks include execution on profitability and market volatility. The stock presents a high-risk opportunity contingent on the company's ability to reverse its negative earnings trend.

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.